Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ATXS Astria Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ATXS
Price (delayed)
$3.9
Market cap
$220.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.68
Enterprise value
$165.63M
Highlights
The company's EPS rose by 31% YoY and by 23% QoQ
Astria Therapeutics's debt has decreased by 5% QoQ
Astria Therapeutics's equity has increased by 31% YoY but it has decreased by 7% QoQ
The net income has declined by 29% year-on-year but it has increased by 6% since the previous quarter
ATXS's quick ratio is down by 22% from the previous quarter and by 20% YoY
Key stats
What are the main financial stats of ATXS
Market
Valuations
Earnings
Shares outstanding
56.43M
Market cap
$220.09M
Enterprise value
$165.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$111.56M
Net income
-$94.26M
EBIT
-$94.26M
EBITDA
-$94.26M
Free cash flow
-$81.54M
Per share
Balance sheet
Liquidity
EPS
-$1.68
EPS diluted
-$1.68
Free cash flow per share
-$1.45
Book value per share
$5.66
Revenue per share
$0
TBVPS
$6.1
Total assets
$342.36M
Total liabilities
$23.1M
Debt
$5.35M
Equity
$319.26M
Working capital
$315.51M
Debt to equity
0.02
Current ratio
17.49
Quick ratio
17.15
Net debt/EBITDA
0.58
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26%
Return on equity
-27.4%
Return on invested capital
-37.5%
Return on capital employed
-29.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATXS stock price
How has the Astria Therapeutics stock price performed over time
Intraday
-10.76%
1 week
-10.76%
1 month
-3.47%
1 year
-59.84%
YTD
-56.38%
QTD
-26.97%
Financial performance
How have Astria Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$111.56M
Net income
-$94.26M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 34% year-on-year but it rose by 4% since the previous quarter
The net income has declined by 29% year-on-year but it has increased by 6% since the previous quarter
Price vs fundamentals
How does ATXS's price correlate with its fundamentals
Growth
What is Astria Therapeutics's growth rate over time
Valuation
What is Astria Therapeutics stock price valuation
P/E
N/A
P/B
0.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 31% YoY and by 23% QoQ
The P/B is 59% lower than the last 4 quarters average of 1.7 and 47% lower than the 5-year quarterly average of 1.3
Astria Therapeutics's equity has increased by 31% YoY but it has decreased by 7% QoQ
Efficiency
How efficient is Astria Therapeutics business performance
The ROIC has soared by 73% YoY and by 25% QoQ
ATXS's ROA is up by 22% YoY and by 12% QoQ
Astria Therapeutics's return on equity has increased by 21% YoY and by 11% QoQ
Dividends
What is ATXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATXS.
Financial health
How did Astria Therapeutics financials performed over time
ATXS's total liabilities has soared by 100% year-on-year and by 16% since the previous quarter
ATXS's total assets is up by 34% YoY but it is down by 5% QoQ
Astria Therapeutics's debt is 98% lower than its equity
Astria Therapeutics's equity has increased by 31% YoY but it has decreased by 7% QoQ
Astria Therapeutics's debt has decreased by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.